Biomoda, Inc. has disclosed that it is again expanding its intellectual property portfolio with an additional unique patent pending to enhance the stability and greatly increase the shelf-life of its assay.
This potentially extraordinary step is looked to both save large sums in testing and expedite bringing to market of Biomoda's patented porphyrin molecule to detect different cell variations of lung cancer.
"Our development work continues to create new methodologies which are not obvious or known. We intend to vigorously protect and capitalize through patent protection," said John Cousins, President of Biomoda.
"This new patent details a number of ways that our onco-labeling solutions have been substantially enhanced," added Dr. Herbert Whitaker, Biomoda's Executive Vice-President and Director of Research. Leslie Robins, Biomoda's Vice-President noted: "It has been a very costly approach (nearly $3,000,000) and it has slowed the Company's entering the marketplace. However, now the Company is firmly in a position to deal with much larger organizations without fear of risking its exclusive position."
John Cousins added: "This additional patent, filed yesterday in Washington D.C., only weeks after the Company's most recent patent filing, underscores the critical importance of protecting and preparing to capitalize on our valuable proprietary technology. We are completing the steps in the Company's plan to link a chain or series of patents which will very soon allow the Company to discuss and disclose its research and aggressively negotiate joint ventures with absolute patent protection in place."